Romidepsin Withdrawn for Peripheral T-Cell Lymphoma

Bristol Myers Squibb has recently made the decision to withdraw romidepsin (Istodax®, Celgene Corporation) from the treatment of patients with peripheral T-cell lymphoma (PTCL) in the United States. In 2011, romidepsin received accelerated approval as monotherapy for the treatment of patients with PTCL. The reason for the withdrawal is due to the results of a phase 3 confirmatory study (NCT01796002), a multicenter trial that randomized 421 patients with previously untreated PTCL to receive romid...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.